No abstract

A new platform for drug, gene and peptide-protein delivery is emerging, under the common name of “extracellular vesicles”. Extracellular vesicles (EVs) are 30-1000 nm-sized cell-derived, liposome-like vesicles. Current research on EVs as nano-delivery systems for small-molecule drugs and genetic material, reveal that these tiny, biologically-derived vesicles carry a great potential to boost the efficacy of many therapeutic protocols. Several features of EVs; from efficacy to safety, from passive to active targeting ability, the opportunity to be biologically or chemically labelled, and most importantly, their eobiotic origin make them promising candidate for development of the next generation personalized nanomedicines. The aim of this article is to provide a view on the current research in which EVs are used as drug/genetic material delivery systems. Their application areas, drug loading and targeting strategies, and biodistribution properties are discussed.This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

The ease of application and no requirement of extra energy input make the microemulsion method favorable for solid lipid nanoparticles (SLNs) production. Very limited data are available to date on preparation of SLNs from pre-screened microemulsion phase diagrams. The purpose of this study was to investigate the microemulsion formation area with solid lipids using hot ternary phase diagrams at elevated temperatures and to use selected microemulsions for SLN production. Also, we aimed to characterize obtained SLNs in terms of physicochemical properties, in vitro cell toxicity, and hemolysis. Phase diagrams of solid lipids were screened at elevated temperatures and oil-in-water microemulsion regions were determined. Microemulsions were selected, and SLNs were produced by modification of the microemulsion dilution method and characterized in terms of visual appearance, turbidity, particle size, and zeta potential. Cytotoxicity of nanoparticles was tested on L929 mouse skin fibroblast cells. Hemolytic potential was assessed in vitro using freshly isolated erythrocytes. The phase diagram screening and the modified hot microemulsion dilution method enabled production of SLNs with particle size below 100 nm. We found evidence that the solid lipids in the SLNs produced by the new method remain in supercooled liquid state. Nanoparticles prepared by the new method exhibit lower toxicity on L929 cells and have lower hemolytic potential than the formulations prepared by direct mixing of the components. The method can be used to prepare SLNs with controllable composition and small particle size below 100 nm. These SLNs are low toxic and can be used for drug delivery purposes.

No abstract

No abstract